CTNM (Contineum Therapeutics, Inc. Class A Common Stock) Stock Financials & Earnings

CTNMContineum Therapeutics, Inc. Class A Common Stock

Mkt Cap$504M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$0

Net Income (TTM)-$60M

EPS (TTM)-$2.18

Free Cash Flow (TTM)-$56M

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$0	-$73K	-$5M
Q2 23	$50M	$50M	$39M
Q3 23	$0	$0	-$8M
Q4 23	$0	$0	-$10M
Q1 24	$0	$0	-$10M
Q2 24	$0	$0	-$11M
Q3 24	$0	$0	-$13M
Q4 24	$0	$0	$85M
Q1 25	$0	$0	-$18M
Q2 25	$0	-$79K	-$18M
Q3 25	$0	-$81K	-$15M
Q4 25	$0	-$85K	-$17M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$4M	—	$1M
Q2 23	$9M	$2M	—
Q3 23	$6M	$2M	—
Q4 23	$8M	$2M	—
Q1 24	$8M	$2M	—
Q2 24	$8M	$3M	—
Q3 24	$10M	$3M	—
Q4 24	$13M	$4M	—
Q1 25	$14M	$4M	—
Q2 25	$14M	$4M	—
Q3 25	$11M	—	$4M
Q4 25	$13M	—	$4M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$6M	$42M	$47M
Q1 23	$0	$94M	$94M
Q3 23	$18M	$118M	$135M
Q4 23	$16M	$110M	$125M
Q1 24	$16M	$102M	$118M
Q2 24	$77M	$141M	$219M
Q3 24	$41M	$173M	$214M
Q4 24	$22M	$183M	$205M
Q1 25	$22M	$168M	$191M
Q2 25	$21M	$155M	$175M
Q3 25	$43M	$140M	$182M
Q4 25	$76M	$187M	$263M

Shares Outstanding

Revenue Per Employee

Revenue / Employee